Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
<b>AIM:</b> To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.<b>METHODS:</b>We performed a comprehensive search of randomized controlled trials...
Main Authors: | Xiao-Yu Zhang, Xiao-Fan Guo, Shao-Dan Zhang, Jing-Na He, Cao-Yu Sun, Yin Zou, Han-Si Bi, Yang Qu |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2014-04-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2014/2/20140230.pdf |
Similar Items
-
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
by: Wen-Jie Wang, et al.
Published: (2015-02-01) -
Comparison of efficacy between Ranibizumab and Conbercept for wet age-related macular degeneration
by: Qiang Fan, et al.
Published: (2018-08-01) -
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01) -
Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01) -
6-weekly bevacizumab versus 4-weekly ranibizumab for neovascular age-related macular degeneration: a 2-year outcome
by: Patrick J Chiam, et al.
Published: (2016-04-01)